Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccine Ročník 41; číslo 35; s. 5072 - 5078
Hlavní autoři: Moros, Alexandra, Prenafeta, Antoni, Barreiro, Antonio, Perozo, Eva, Fernández, Alex, Cañete, Manuel, González, Luis, Garriga, Carme, Pradenas, Edwards, Marfil, Silvia, Blanco, Julià, Cebollada Rica, Paula, Sisteré-Oró, Marta, Meyerhans, Andreas, Prat Cabañas, Teresa, March, Ricard, Ferrer, Laura
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier Ltd 07.08.2023
Elsevier Limited
Témata:
Allergy and Immunology
Amino acids
Animal models
Antibodies
COVID-19
COVID-19 infection
COVID-19 vaccines
Disease transmission
domain
Hogs
Humoral immune response
humoral immunity
IFNγ
Immune response
Immune response (humoral)
Immune system
Immunization
Immunogenicity
Lymphocytes T
Males
mice
Pandemics
Proteins
RBD
Recombinant vaccine
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Swine
T-lymphocytes
Temperature
Vaccines
Within-subjects design
γ-Interferon
COVID-19
IFNγ
Humoral immune response
SARS-CoV-2
RBD
Recombinant vaccine
ISSN:0264-410X, 1873-2518, 1873-2518
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (RBD) of the Beta variant of SARS-CoV-2 fused in tandem with the equivalent domain of the Alpha variant, with its immunogenicity, safety and efficacy previously demonstrated in mouse models. In the present study, we immunized pigs with different doses of PHH-1V in a prime-and-boost scheme showing PHH-1V to exhibit an excellent safety profile in pigs and to produce a solid RBD-specific humoral response with neutralising antibodies to 7 distinct SARS-CoV-2 variants of concern, with the induction of a significant IFNγ+ T-cell response. We conclude that PHH-1V is safe and elicits a robust immune response to SARS-CoV-2 in pigs, a large animal preclinical model.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2023.07.008